CLINICAL TRIALS PROFILE FOR SHR3162
✉ Email this page to a colleague
Clinical Trials for SHR3162
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02747342 ↗ | A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer | Completed | Atridia Pty Ltd. | Phase 1 | This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety, tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with metastatic castration-resistant prostate cancer (mCRPC). |
| NCT02759666 ↗ | A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors | Completed | Atridia Pty Ltd. | Phase 1 | This is an open-label, multicenter, non-randomized, dose-escalation phase 1 trial to evaluate the safety and tolerability of SHR3162 in participants with advanced solid tumors. |
| NCT03075462 ↗ | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | Unknown status | Beijing Cancer Hospital | Phase 1 | Fluzoparib is an oral potent, selective poly-ADP ribose polymerase-1 (PARP-1) and PARP-2 inhibitor; Apatinib is an oral selective vascular endothelial growth factor receptor (VEGFR) inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best dose of fluzoparib in combination with apatinib and to see how well these two drugs work together in the treatment of patients with recurrent ovarian cancer or triple negative breast cancer. The safety and efficacy of fluzoparib in combination with apatinib will be explored. Both dose escalation and dose expansion parts are included in this study. |
| NCT03075462 ↗ | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | Unknown status | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Fluzoparib is an oral potent, selective poly-ADP ribose polymerase-1 (PARP-1) and PARP-2 inhibitor; Apatinib is an oral selective vascular endothelial growth factor receptor (VEGFR) inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best dose of fluzoparib in combination with apatinib and to see how well these two drugs work together in the treatment of patients with recurrent ovarian cancer or triple negative breast cancer. The safety and efficacy of fluzoparib in combination with apatinib will be explored. Both dose escalation and dose expansion parts are included in this study. |
| NCT03182673 ↗ | The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors | Unknown status | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | The study consists of the two parts, the first one is SHR7390 combined with SHR-1210, the second one is SHR7390 combined with SHR-1210 and SHR3162. Two parts of the study are separately to assess the safety and tolerability, to define dose limiting toxicity（DLT) and maximum tolerated dose (MTD),to evaluate the pharmacokinetics ,to assess the antitumor activity in patients with advanced solid tumors preliminarily and to recommend reasonable dosage regimen of SHR7390 for the follow-up clinical trial. |
| NCT03509636 ↗ | A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer | Completed | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | This is a multicenter， open-label study to evluate the efficacy and safety of a novel PARP 1/2 inhibitor fluzoparib （SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for SHR3162
Condition Name
Clinical Trial Locations for SHR3162
Clinical Trial Progress for SHR3162
Clinical Trial Phase
Clinical Trial Sponsors for SHR3162
Sponsor Name
